Certain identified information has been marked in the exhibit because it is both
(i) not material and (ii) would likely cause competitive harm to the Company, if
publicly disclosed.
Double asterisks denote omissions.

AMENDMENT TO
MASTER RESEARCH AND COLLABORATION AGREEMENT
        This Amendment to Master Research and Collaboration Agreement (this
“Amendment”) is entered into as of February 5, 2020 (the “Amendment Date”), by
and among Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”), on the
one hand, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”),
with respect to all rights and obligations under the Master Collaboration
Agreement (as defined below) in the United States, and Celgene RIVOT Ltd., a
Bermuda entity (“Celgene RIVOT”), with respect to all rights and obligations
under the Master Collaboration Agreement outside of the United States (Celgene
RIVOT and Celgene Corp. together, “Celgene”), on the other hand. Capitalized
terms used herein and not defined herein shall have the meanings ascribed to
them in the Master Collaboration Agreement.
        WHEREAS, the Parties entered into that certain Master Research and
Collaboration Agreement, dated as of May 17, 2016 (the “Master Collaboration
Agreement”), pursuant to which Celgene obtained exclusive options to obtain
certain rights to participate in the development and commercialization of
Compounds and Products arising out of activities conducted pursuant to certain
research and development programs under the Master Collaboration Agreement and
to share profits and losses arising from the development and commercialization
of such Compounds and Products on a worldwide basis; and
        WHEREAS, the Parties previously entered into a certain Appendix
Substitution Agreement dated as of January 29, 2019, relating to the Master
Collaboration Agreement;
        NOW THEREFORE, the Parties are entering into this Amendment to provide
for (i) a modification to the notice period for extensions of the Research Term
and (ii) an extension of the Option Exercise Window solely with respect to the
[**], in each case as set forth below.
1. Amendment Relating to Research Term.
Section 2.1.2(a) of the Master Collaboration Agreement is hereby deleted and
replaced in its entirety with the following:
“2.1.2(a) Initial Extension Right. Celgene may, at its election, extend the
Research Term for up to two (2) one (1) year extension periods (each to run
consecutively after the end of the then-current Research Term) by giving notice
to Agios of its election (i) in the case of the first one (1) year extension
period, by no later than [**] and (ii) in the case of the second one (1) year
extension period, at least [**] prior to the expiration of the then-current
Research Term, and (in each case (i) and (ii)) by paying the Research Term
Extension Fee as set forth in Section 6.3.”
2. Amendment Relating to the Option Exercise Window with respect to the [**].

--------------------------------------------------------------------------------

(a) Prior to the Amendment Date, Agios provided to Celgene an Option Data
Package for the [**]. Celgene acknowledges receipt of such Option Data Package.
(b) The Option Exercise Window applicable to the [**] is hereby amended to
continue through [**] and to expire at the end of such day.
3. Continued Effectiveness of Master Collaboration Agreement. As amended hereby,
the Master Collaboration Agreement remains in full force and effect.
[Signature Pages Follow]

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have
caused this Amendment to be executed by their respective duly authorized
officers as of the date first written above.
CELGENE CORPORATION
By: /s/ Susana Parathath Name: Susana ParathathTitle: Dir Global Alliances
[Signature Page to Amendment to Master Research and Collaboration Agreement]

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have
caused this Amendment to be executed by their respective duly authorized
officers as of the date first written above.

Solely with respect to the rights and obligations under the Master Collaboration
Agreement outside of the United States (subject to Section 12.13 of the Master
Collaboration Agreement):
CELGENE RIVOT LTD.
By: /s/ Kevin Mello  Name: Kevin MelloTitle: Director
[Signature Page to Amendment to Master Research and Collaboration Agreement]

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have
caused this Amendment to be executed by their respective duly authorized
officers as of the date first written above.
AGIOS PHARMACEUTICALS, INC.
By: /s/ Andrew Hirsch Name: Andrew HirschTitle: Chief Financial Officer
[Signature Page to Amendment to Master Research and Collaboration Agreement]